Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;49(6):1939-1950.
doi: 10.1007/s00259-021-05666-9. Epub 2022 Jan 5.

Metabolic correlates of olfactory dysfunction in COVID-19 and Parkinson's disease (PD) do not overlap

Silvia Morbelli  1   2 , Silvia Chiola  3   4 , Maria Isabella Donegani  5   6 , Dario Arnaldi  5   7 , Matteo Pardini  5   7 , Raffaele Mancini  5   7 , Francesco Lanfranchi  5   6 , Francesca D'amico  5   6 , Matteo Bauckneht  5   6 , Alberto Miceli  5   6 , Erica Biassoni  5   7 , Beatrice Orso  5   7 , Emanuela Barisione  8 , Luana Benedetti  5   7 , Sambuceti Gianmario  5   6 , Flavio Nobili  5   7
Affiliations

Metabolic correlates of olfactory dysfunction in COVID-19 and Parkinson's disease (PD) do not overlap

Silvia Morbelli et al. Eur J Nucl Med Mol Imaging. 2022 May.

Abstract

Purpose: Hyposmia is a common feature of COVID-19 and Parkinson's disease (PD). As parkinsonism has been reported after COVID-19, a link has been hypothesized between SARS-CoV2 infection and PD. We aimed to evaluate brain metabolic correlates of isolated persistent hyposmia after mild-to-moderate COVID-19 and to compare them with metabolic signature of hyposmia in drug-naïve PD patients.

Methods: Forty-four patients who experienced hyposmia after SARS-COV2 infection underwent brain [18F]-FDG PET in the first 6 months after recovery. Olfaction was assessed by means of the 16-item "Sniffin' Sticks" test and patients were classified as with or without persistent hyposmia (COVID-hyposmia and COVID-no-hyposmia respectively). Brain [18F]-FDG PET of post-COVID subgroups were compared in SPM12. COVID-hyposmia patients were also compared with eighty-two drug-naïve PD patients with hyposmia. Multiple regression analysis was used to identify correlations between olfactory test scores and brain metabolism in patients' subgroups.

Results: COVID-hyposmia patients (n = 21) exhibited significant hypometabolism in the bilateral gyrus rectus and orbitofrontal cortex with respect to COVID-non-hyposmia (n = 23) (p < 0.002) and in middle and superior temporal gyri, medial/middle frontal gyri, and right insula with respect to PD-hyposmia (p < 0.012). With respect to COVID-hyposmia, PD-hyposmia patients showed hypometabolism in inferior/middle occipital gyri and cuneus bilaterally. Olfactory test scores were directly correlated with metabolism in bilateral rectus and medial frontal gyri and in the right middle temporal and anterior cingulate gyri in COVID-hyposmia patients (p < 0.006) and with bilateral cuneus/precuneus and left lateral occipital cortex in PD-hyposmia patients (p < 0.004).

Conclusion: Metabolic signature of persistent hyposmia after COVID-19 encompasses cortical regions involved in olfactory perception and does not overlap metabolic correlates of hyposmia in PD.

Keywords: Anosmia; Brain PET; COVID-19; Parkinson’s disease; [18F]FDG.

PubMed Disclaimer

Conflict of interest statement

Silvia Morbelli received speaking honoraria from GE Healthcare and AAA. Flavio Nobili received fees from BIAL for consultation, from GE Healthcare for teaching talks, and from Roche for board participation. Dario Arnaldi received fees from Fidia for lectures and board participation. Matteo Pardini receives research support from Novartis and Nutricia and fees from Novartis, Merck, and Biogen. All other authors declare no competing interests.

Figures

Fig. 1
Fig. 1
A, B Schematic representation of the steps that narrowed post-COVID and de novo PD subgroups to the final number of patients
Fig. 2
Fig. 2
Correlation between Sniffin-test scores and whole-brain metabolism in COVID-hyposmia (A) and PD-hyposmia patients (B). A significant direct correlation was highlighted between olfaction and brain metabolism in rectus, middle temporal, and medial frontal gyri on both hemispheres and in the right precentral gyrus and anterior cingulate in COVID-hyposmia patients and in cuneus/precuneus on both hemispheres and in the lateral occipital cortex in the left hemisphere in PD-hyposmia patients. Clusters with significant hypometabolism are shown superimposed on an MRI template. The color bars indicate the level of z-scores for significant voxels. (See Table 2 for details on coordinates and z-scores.)
Fig. 3
Fig. 3
A, B Results of the ANOVA statistical model comparing the three groups of patients (COVID-hyposmia, COVID-non-hyposmia, and PD-hyposmia) with age and sex as nuisance variables. Clusters with significant hypometabolism are shown superimposed on a 3D brain rendering. Direct comparison between patients subgroups was explored in the post hoc analyses (Fig. 4A–C)
Fig. 4
Fig. 4
Comparisons between COVID-hyposmia on one side and COVID-non-hyposmia and PD-hyposmia respectively. COVID-hyposmia patients showed significant hypometabolism with respect to COVID-non-hyposmia in a bilateral and symmetric cluster encompassing gyrus rectus and inferior, middle, and superior frontal gyrus (A) while (changing the direction of the contrast) no regions of significant hypometabolism were identified in COVID-non-hyposmia. With respect to PD-hyposmia patients COVID-hyposmia patients showed hypometabolism in middle and superior temporal gyri, medial, and middle frontal gyri on both hemispheres and right insula (B). PD-hyposmia patients showed relative hypometabolism with respect to COVID-hyposmia in wide cortical regions mainly involving inferior and middle occipital gyri and cuneus in both hemispheres (C). Clusters with significant hypometabolism are shown superimposed on an MRI template. The color bars indicate the level of z-scores for significant voxels. (See Tables 3 and 4 for details on coordinates and z-scores.)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, Kneen R, Defres S, Sejvar J, Solomon T. Neurological associations of COVID-19. Lancet Neurol. 2020;19:767–783. doi: 10.1016/S1474-4422(20)30221-0. - DOI - PMC - PubMed
    1. Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020;277:2251–2261. doi: 10.1007/s00405-020-05965-1. - DOI - PMC - PubMed
    1. Boscolo-Rizzo P, Polesel J, Spinato G, Menegaldo A, Fabbris C, Calvanese L, Borsetto D, Hopkins C. Predominance of an altered sense of smell or taste among long-lasting symptoms in patients with mildly symptomatic COVID-19. Rhinology. 2020;58:524–525. doi: 10.4193/Rhin20.263. - DOI - PubMed
    1. Estiri H, Strasser ZH, Brat GA, Semenov YR, Patel CJ, Murphy SN. Evolving phenotypes of non-hospitalized patients that indicate long COVID 2021. 10.1101/2021.04.25.21255923 - PMC - PubMed
    1. Almeria M, Cejudo JC, Sotoca J, Deus J, Krupinski J. Cognitive profile following COVID-19 infection: clinical predictors leading to neuropsychological impairment. Brain Behav Immun Health. 2020;9:100163. doi: 10.1016/j.bbih.2020.100163. - DOI - PMC - PubMed